Home » Stocks » KIN

Kindred Biosciences, Inc. (KIN)

Stock Price: $4.83 USD 0.07 (1.47%)
Updated May 18, 2021 1:17 PM EDT - Market open
Market Cap 205.09M
Revenue (ttm) 43.96M
Net Income (ttm) -8.78M
Shares Out 41.09M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $4.83
Previous Close $4.76
Change ($) 0.07
Change (%) 1.47%
Day's Open 4.76
Day's Range 4.73 - 4.92
Day's Volume 134,024
52-Week Range 3.20 - 6.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Shares of Kindred Biosciences (NASDAQ:KIN) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 46.67% year over year to ($0.24), which were in line with the e...

6 days ago - Benzinga

SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for ...

6 days ago - PRNewsWire

SAN FRANCISCO, May 3, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 fin...

2 weeks ago - PRNewsWire

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the United Stat...

2 weeks ago - PRNewsWire

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a...

3 weeks ago - PRNewsWire

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a 9.31% stake in Kindred Biosciences Inc. (NASDAQ:KIN) earlier this week.

1 month ago - GuruFocus

Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SAN FRANCISCO, March 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results fo...

2 months ago - PRNewsWire

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SAN FRANCISCO, Feb. 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted...

2 months ago - PRNewsWire

SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities A...

3 months ago - PRNewsWire

SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed ...

3 months ago - PRNewsWire

SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from...

4 months ago - PRNewsWire

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND-030, a fi...

Other stocks mentioned: ELAN
5 months ago - Business Wire

SAN FRANCISCO, Dec. 2, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin,...

5 months ago - PRNewsWire

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and 82.98%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for ...

6 months ago - PRNewsWire

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2020 f...

6 months ago - PRNewsWire

SAN FRANCISCO, Sept. 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc.

8 months ago - PRNewsWire

SAN FRANCISCO, Sept. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc.

8 months ago - PRNewsWire

Two Sample Breakout Stocks for Week 36 with better than 10% short-term upside potential. Now up an average 183.6% YTD.

Other stocks mentioned: AAPL, CVX, EXK, HD, JNJ, MRK, PFE ...
8 months ago - Seeking Alpha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AWR, CLRB, CVEO, POR
8 months ago - Zacks Investment Research

Kindred Biosciences, Inc.'s (KIN) CEO Richard Chin on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of 333.33% and 100.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Kindred Bio (KIN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

Investors need to pay close attention to Kindred Biosciences (KIN) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

SAN FRANCISCO, June 8, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its ...

11 months ago - PRNewsWire

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of -5.26% and -3.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of -11.43% and -28.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Kindred Biosciences' (KIN) CEO Richard Chin on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: ADAP, CLDR, FLMN, ZNGA
1 year ago - 24/7 Wall Street

Kindred Biosciences'(KIN) CEO Richard Chin on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

KIN earnings call for the period ending December 31, 2018.

2 years ago - The Motley Fool

About KIN

Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) rec... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Dec 12, 2013
CEO
Richard Chin
Employees
63
Stock Exchange
NASDAQ
Ticker Symbol
KIN
Full Company Profile

Financial Performance

In 2020, KIN's revenue was $42.16 million, an increase of 890.70% compared to the previous year's $4.26 million. Losses were -$21.80 million, -64.50% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for KIN stock is "Buy." The 12-month stock price forecast is 11.75, which is an increase of 143.27% from the latest price.

Price Target
$11.75
(143.27% upside)
Analyst Consensus: Buy